TABLE 2.
Risk of NAFLD in Patients With Type 2 Diabetes Using TZDs Compared With SUs
| Exposure to Glucose‐Lowering Agents | Risk of NAFLD | ||||
|---|---|---|---|---|---|
| No. of Events (n = 2,526) | PYs | IR/1,000 PYs | Age/Sex aHR (95% CI) | aHR (95% CI)† | |
| Current Use of Glucose‐Lowering Agents | |||||
| SUs | 616 | 172,309 | 3.6 | Reference | Reference |
| TZDs | 18 | 14,732 | 1.2 | 0.32 (0.20‐0.51) | 0.32 (0.20‐0.51) |
| DPP‐4 inhibitors | 159 | 45,677 | 3.5 | 0.92 (0.77‐1.09) | 0.86 (0.72‐1.02) |
| Other glucose‐lowering agents † | 1,553 | 459,614 | 3.4 | 0.87 (0.79‐0.95) | 0.94 (0.85‐1.03) |
| Concurrent use | |||||
| TZDs and SUs | 20 | 9,624 | 2.1 | 0.56 (0.36‐0.88) | 0.56 (0.36‐0.87) |
| Past use | |||||
| Past use of any glucose‐lowering agent | 160 | 363,620 | 0.4 | 0.10 (0.09‐0.12) | 0.15 (0.12‐0.18) |
All groups in this table were mutually exclusive. Current use (1‐90 days) or past use (>90 days) were defined by the time since the most recent prescription.
*
Statistically adjusted for age, sex, BMI, HbA1c, and use of systemic glucocorticoids and all other exposure categories in this table.
†
Use of glucose‐lowering agents other than SUs, TZDs, and DPP‐4 inhibitors.
Abbreviations: IR, incidence rate; PYs, person‐years.